Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/ cyclophosphamide (TEC) in stage II and III breast cancer

Breast Journal

Volumn 13, Issue 3, 2007, Pages 274-280

  Burdette Radoux, Susan ^a   Wood, Marie E ^a   Olin, Julie J ^a   Laughlin, Rebecca S ^a   Crocker, Abigail M ^a   Ashikaga, Takamaru ^a   Muss, Hyman B ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Chemotherapy; Clinical trial; Neoadjuvant

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; EDEMA; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART FUNCTION; HUMAN; HYPOPHOSPHATEMIA; INSOMNIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE RETENTION; VOMITING;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEASIBILITY STUDIES; FEMALE; FILGRASTIM; HUMANS; INJECTIONS, SUBCUTANEOUS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEUTROPENIA; TAXOIDS; THROMBOPHLEBITIS; TREATMENT OUTCOME;

EID: 34247489122     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2007.00421.x     Document Type: Article

References (28)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 365 : 1687 717.
2. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003 21 : 3357 65.
3. The National Institutes of Health Consensus Development Conference. Adjuvant therapy for breast cancer. Bethesda, Maryland, USA. November 1-3, 2000. Proceedings. J Natl Cancer Inst Monogr 2001 30 : 1 152.
4. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003 21 : 4165 74.
5. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002 20 : 1456 66.
6. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003 21 : 976 83.
7. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005 23 : 3686 96.
8. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005 352 : 2302 13.
9. Perez DJ, Harvey VJ, Robinson BA, et al. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 1991 9 : 2148 52.
10. Levine MN, Pritchard KI, Bramwell VCH, et al. A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer: update of NCIC CTG MA.5. Breast Cancer Res Treat 2002 76 (Suppl 1 S33 000.
11. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998 16 : 2651 8.
12. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001 19 : 602 11.
13. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003 21 : 1431 9.
14. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000 18 : 2522 8.
15. Moore T, Larrimer N. Pegfilgrastim minimizes hematologic toxicity and supports dose-dense CHOP-R. Ann Oncol 2002 13 : 169.
16. Burstein HJ, Parker LM, Keshaviah A, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005 23 : 8340 7.
17. NCI CTEP Common Toxicity Criteria v2.0. National Cancer Institute. 1999
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92 : 205 16.
19. Evans TR, Yellowlees A, Foster E, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol 2005 23 : 2988 95.
20. Espinosa E, Morales S, Borrega P, et al. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemother Pharmacol 2004 54 : 546 52.
21. Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 2005 97 : 1724 33.
22. Fountzilas G, Papadimitriou C, Aravantinos G, et al. Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer. Oncology 2001 60 : 214 20.
23. Dang CT, D'Andrea GM, Moynahan ME, et al. Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clin Cancer Res 2004 10 : 5754 61.
24. Margolis JH, Zekman R. Toxicity and tolerability of dose dense (q 14 days) docetaxel (T)/ doxorubicin (A)/ cyclophosphamide (C) (TAC) in stage II - III breast cancer. J Clin Oncol 2005 23 (16S 76s.
25. Kirkova J, Davis MP, Walsh D, et al. Cancer symptom assessment instruments: A systematic review. J Clin Oncol 2006 24 : 1459 73.
26. O'Regan RM, Von Roenn JH, Carlson RW, et al. Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer. Clin Breast Cancer 2005 6 : 163 8.
27. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998 16 : 2672 85.
28. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999 17 : 460 9.